NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Sorevna, a leader in natural skincare solutions, proudly announces the launch of its innovative all-natural cream, designed to address even the toughest calluses and extremely dry skin. This groundbreaking formula offers a gentle yet effective solution for a wide range of individuals, from those with occupational skin concerns to those managing specific skin conditions.
A Natural Solution for Diverse Needs
Sorevna’s new cream is formulated to meet the needs of:
Individuals with very thick, dry, and callused skin
People who spend long hours on their feet
Those who are ingredient-conscious or sensitive to harsh chemicals
Environmentally-conscious individuals seeking cruelty-free products
Anyone seeking visible results within weeks
What sets this cream apart is its all-natural formula, free from harsh chemicals and preservatives, making it suitable for all genders and skin types.
Fast-Acting and Effective
“Our goal was to create a product that delivers results quickly without compromising on safety or natural ingredients,” said Dr. James A. Wright, CEO of Sorevna. “We’re thrilled to offer a solution that can make a noticeable difference in just a few weeks.”
Versatile Application
The cream’s versatility makes it an ideal choice for a broad spectrum of users, from healthcare workers and service industry professionals to individuals managing chronic skin conditions. Its natural composition ensures it’s gentle enough for daily use while potent enough to tackle stubborn skin issues.
Availability
Sorevna’s all-natural cream is now available for purchase on the company’s website and at select retailers nationwide.
For more information about Sorevna and its new all-natural cream, please visit www.sorevna.com.
About Sorevna:
Sorevna is a leading producer of cruelty-free, organic cosmetic products designed to address the daily stresses on the hands, feet, and face.
Media Contact
Mary Junsay
201-571-0900
help@sorevna.com
SOURCE: Sorevna
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…